User login
The Tax Cuts and Jobs Act passed by Congress and signed into law by President Trump includes a reduction of the Orphan Drug Tax Credit (ODTC), a repeal of the Affordable Care Act’s individual mandate, and a temporary bolstering of the Medical Expense Deduction. While NORD supports the temporary strengthening of the Medical Expense Deduction, it opposed the repeal of the individual mandate and the reduction of the ODTC. Thanks to the work of rare disease advocates joining NORD in support for the ODTC, the tax credit was not repealed entirely, as was initially suggested, but rather was cut in half. NORD is grateful for the support it received on this issue and will continue to work to preserve the important orphan drug incentives in 2018.
The Tax Cuts and Jobs Act passed by Congress and signed into law by President Trump includes a reduction of the Orphan Drug Tax Credit (ODTC), a repeal of the Affordable Care Act’s individual mandate, and a temporary bolstering of the Medical Expense Deduction. While NORD supports the temporary strengthening of the Medical Expense Deduction, it opposed the repeal of the individual mandate and the reduction of the ODTC. Thanks to the work of rare disease advocates joining NORD in support for the ODTC, the tax credit was not repealed entirely, as was initially suggested, but rather was cut in half. NORD is grateful for the support it received on this issue and will continue to work to preserve the important orphan drug incentives in 2018.
The Tax Cuts and Jobs Act passed by Congress and signed into law by President Trump includes a reduction of the Orphan Drug Tax Credit (ODTC), a repeal of the Affordable Care Act’s individual mandate, and a temporary bolstering of the Medical Expense Deduction. While NORD supports the temporary strengthening of the Medical Expense Deduction, it opposed the repeal of the individual mandate and the reduction of the ODTC. Thanks to the work of rare disease advocates joining NORD in support for the ODTC, the tax credit was not repealed entirely, as was initially suggested, but rather was cut in half. NORD is grateful for the support it received on this issue and will continue to work to preserve the important orphan drug incentives in 2018.